A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Trial Profile

A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Registrational
  • Acronyms APPRISE; ODYSSEY APPRISE
  • Sponsors Sanofi
  • Most Recent Events

    • 30 Aug 2017 Interim results (n=843) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 25 Aug 2017 According to a Regeneron Pharmaceuticals media release, data will be presented at the European Society of Cardiology (ESC) Congress 2017.
    • 10 Aug 2017 Planned End Date changed from 1 May 2019 to 27 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top